NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Black Diamond Therapeutics Inc (NASDAQ: BDTX)

 
BDTX Technical Analysis
5
As on 19th Mar 2025 BDTX STOCK Price closed @ 1.72 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.23 & Strong Sell for SHORT-TERM with Stoploss of 2.27 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

BDTXSTOCK Price

Open 2.36 Change Price %
High 2.78 1 Day 0.04 2.38
Low 1.71 1 Week 0.01 0.58
Close 1.72 1 Month -0.82 -32.28
Volume 113914632 1 Year -1.06 -38.13
52 Week High 7.39 | 52 Week Low 1.65
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
NVDA 117.52 1.81%
INTC 24.12 -6.94%
LCID 2.44 3.83%
LMDX 0.02 0.00%
BDTX 1.72 2.38%
TSLA 235.86 4.68%
AKTS 0.04 0.00%
PLUG 1.58 -2.47%
VRPX 0.11 -15.38%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
BCAC 22.71 125.30%
CFFEW 0.11 120.00%
JCIC 22.08 116.68%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
LILM 0.05 -79.17%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
BPTH 0.21 -66.67%
TFFP 0.06 -62.50%
MILEW 0.06 -53.85%
ZWZZT 20.68 -52.11%
 
 
BDTX
Daily Charts
BDTX
Intraday Charts
Whats New @
Bazaartrend
BDTX
Free Analysis
 
BDTX Important Levels Intraday
RESISTANCE3.78
RESISTANCE3.12
RESISTANCE2.71
RESISTANCE2.30
SUPPORT1.14
SUPPORT0.73
SUPPORT0.32
SUPPORT-0.34
 
BDTX Forecast March 2025
4th UP Forecast3.42
3rd UP Forecast2.87
2nd UP Forecast2.54
1st UP Forecast2.2
1st DOWN Forecast1.24
2nd DOWN Forecast0.9
3rd DOWN Forecast0.57
4th DOWN Forecast0.02
 
BDTX Weekly Forecast
4th UP Forecast3.05
3rd UP Forecast2.62
2nd UP Forecast2.36
1st UP Forecast2.10
1st DOWN Forecast1.34
2nd DOWN Forecast1.08
3rd DOWN Forecast0.82
4th DOWN Forecast0.39
 
BDTX Forecast2025
4th UP Forecast13.42
3rd UP Forecast9.67
2nd UP Forecast7.35
1st UP Forecast5.03
1st DOWN Forecast-1.59
2nd DOWN Forecast-3.91
3rd DOWN Forecast-6.23
4th DOWN Forecast-9.98
 
 
BDTX Other Details
Segment EQ
Market Capital 285363968.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
BDTX Address
BDTX
 
BDTX Latest News
 
Your Comments and Response on Black Diamond Therapeutics Inc
 
BDTX Business Profile
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. Address: One Main Street, Cambridge, MA, United States, 02142
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service